New on YCharts: We've added nearly 10,000 securities to our database with coverage of OTCMARKETS HIDE

Tekmira Pharmaceuticals Corporation (TKMR)

Create an Alert
4.80 -0.02  -0.41%   NASDAQ Jun 17, 8:00PM BATS Real time Currency in USD

Tekmira Pharmaceuticals Corporation R&D Expense Quarterly

View Full Chart

Tekmira Pharmaceuticals Corporation R&D Expense Quarterly Chart

    Tekmira Pharmaceuticals Corporation Historical R&D Expense Quarterly Data

    Pro Data Export
    Dates:  to
    Viewing 1 of 1   First  Previous First    Next  Last   Last

    There is no data for the selected date range.

    Data for this Date Range  
    Dec. 31, 2008 2.515M
    Sept. 30, 2008 5.198M
    June 30, 2008 5.611M
    March 31, 2008 Go Pro
       
    Dec. 31, 2007 Go Pro
    Sept. 30, 2007 Go Pro
    June 30, 2007 Go Pro

    About R&D Expense

    R&D expenses are a line item from many companies' income statements.

    R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.

    Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.

    An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
    Learn More

    Get data for

    TKMR R&D Expense Quarterly Benchmarks

    Companies
    Alnylam Pharmaceuticals 22.18M
    Talon Therapeutics 2.652M
    Arqule 8.181M

    TKMR R&D Expense Quarterly Range, Past 5 Years

    Minimum 2.515M Dec 2008
    Maximum 5.611M Jun 2008
    Average 4.442M

    Access watchlists and custom data alerts.
    Start your free account.

    Registering enables you to view unlimited pages per month.

    required
    required
    required
    required
    Get Started Now

    Already registered? Sign in here.

    document.write('');